Trial Profile

A Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ATI-045 in Patients With Moderate-to-Severe Atopic Dermatitis

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 15 Jul 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

18 Mar 2026 Status changed from recruiting to active, no longer recruiting,According to a Aclaris Therapeutics media release.
18 Mar 2026 According to a Aclaris Therapeutics media release, patient enrollment have been completed in this trial and Top line results are expected in the fourth quarter of 2026.
02 Jun 2025 According to a Aclaris Therapeutics media release, company expect to provide top line results from this trial in the second half of 2026

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com